Premium
Microcrack Frequency and Bone Remodeling in Postmenopausal Osteoporotic Women on Long‐Term Bisphosphonates: A Bone Biopsy Study
Author(s) -
Chapurlat Roland D,
Arlot Monique,
BurtPichat Brigitte,
Chavassieux Pascale,
Roux Jean Paul,
PorteroMuzy Nathalie,
Delmas Pierre D
Publication year - 2007
Publication title -
journal of bone and mineral research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.882
H-Index - 241
eISSN - 1523-4681
pISSN - 0884-0431
DOI - 10.1359/jbmr.070609
Subject(s) - medicine , bone remodeling , cancellous bone , osteoporosis , calcein , endocrinology , urology , biopsy , dentistry , pathology , chemistry , biochemistry , membrane
We sought whether microdamage could rise in postmenopausal osteoporotic women on long‐term bisphosphonates, as suggested by recent animal studies. We found few microcracks in iliac bone biopsies, despite a marked reduction in bone turnover. Introduction: Animal studies suggest that bisphosphonates (BPs) could increase microdamage frequency in a dose‐dependent manner, caused by excessively suppressed bone turnover. However, there is limited data in humans receiving BP therapeutic doses for >3 yr. Materials and Methods: We measured microcrack frequency and histomorphometry parameters on transiliac bone biopsies in 50 postmenopausal osteoporotic women (mean age = 68 yr) who had received BP therapy (3 on intravenous pamidronate, 37 on oral alendronate, and 10 on oral risedronate) for at least 3 yr (mean treatment duration = 6.5 yr). We compared these results with transiliac bone biopsies obtained from 12 cadavers. We used bulk staining with green calcein as a fluorochrome. The microcracks were quantified in three 100‐μm‐thick sections using optic microscopy and were confirmed by laser confocal microscopy. Microcrack frequency (number of microcracks/mm 2 of bone tissue) was compared between treated women and controls using nonparametric tests. We also explored predictors of microcrack frequency, including age, duration of BP therapy, and activation frequency. Results: Among treated women, cancellous bone microcrack frequency was low (mean, 0.13 microcracks/mm 2 ) and did not differ significantly from that observed in controls (0.05 microcracks/mm 2 ; p = 0.59). Of note, 54% of the treated women and 58% of the controls had no observable microcracks. There was no association between microcrack frequency and the duration of BP therapy (for microcracks/mm 2 and duration, Spearman r = 0.04, p = 0.80) and between patients' ages and the number of microcracks (Spearman r = −0.09, p = 0.61). Although bone remodeling parameters were suppressed in treated women, we found no relationship between microcrack density and activation frequency (Spearman r = −0.003, p = 0.99). Also, microcrack frequency was not increased in women with prevalent vertebral fracture compared with those without fractures. Conclusions: Among postmenopausal osteoporotic women on long‐term BPs, microcrack frequency in the iliac bone is low, despite a marked reduction of bone turnover.